Page 2 - Syngene International
Syngene International Q1 PAT slips 4% to Rs 74 cr; revenue rises 8%
Contract manufacturing services firm Syngene International on Wednesday reported a 4 per cent decline in profit after tax to Rs 74 crore for the first quarter ended June 2022. The company had posted a PAT of Rs 77 crore in the April-June quarter of last fiscal. Its revenue from operations rose to Rs 644 crore in the first quarter against Rs 595 crore in the year-ago period, the company said in a statement. The first quarter results were against a strong quarter last year due to sales of Remdesivir, it added. Excluding the impact of Remdesivir, the underlying revenue from operations growth in the quarter stood at around 30 per cent year-on-year, it stated. "The first quarter results were in line with our expectations and reflect strong underlying performance across all our business divisions. The contribution from the development and manufacturing services divisions drove the growth momentum against a low base in the previous year," Syngene International MD and CEO Jonathan Hunt ..
 "Syngene International Q1 PAT slips 4% to Rs 74 cr; revenue rises 8%")
Stocks to Watch: RIL, HUL, ONGC, NTPC, Ambuja, HDFC Life, Grasim, Vedanta
Stocks to Watch Today: CEAT, Havells, IndusInd Bank, Mastek, OFSS, RIIL, Syngene International, Tata Communications and Wirpo to announce Q1 results on Wednesday.
 "Stocks to Watch: RIL, HUL, ONGC, NTPC, Ambuja, HDFC Life, Grasim, Vedanta")
Deal with Zoetis could be worth $500 mn in 10 yrs: Syngene In'l chief
In a Q&A, Jonathan Hunt, MD & CEO of the Biocon arm, dwells on his firm's initiatives to overcome supply chain bottlenecks and other issues
 "Deal with Zoetis could be worth $500 mn in 10 yrs: Syngene In'l chief")
Stocks to watch: ACC, L&T Tech, L&T Infotech, JSPL, Glenmark, Tata Elxsi
Stocks to watch today: L&T Technology Services and Jindal Steel and Power will share June quarter 2022 (Q1FY23) results on Friday, July 15.
 "Stocks to watch: ACC, L&T Tech, L&T Infotech, JSPL, Glenmark, Tata Elxsi")
Syngene International signs 10-year agreement with US-based firm Zoetis
Librela or bedinvetmab has already been launched in Europe and the UK, and has won 'Best new companion animal product' by IHS Markit Connect in 2021
 "Syngene International signs 10-year agreement with US-based firm Zoetis")
Biocon arm Syngene ends contract with Bioinnovat Research over graft case
Guljit Sethi of Bioinnovat was named in CBI FIR on a bribery case involving CDSCO official and Biocon Biologics executive
 "Biocon arm Syngene ends contract with Bioinnovat Research over graft case")
Syngene's Q4 PAT up 7% to Rs 148 cr; revenue rises 15% to Rs 758 cr
The company had reported a PAT of Rs 138 crore in the January-March period of 2020-21
 "Syngene's Q4 PAT up 7% to Rs 148 cr; revenue rises 15% to Rs 758 cr")
3 stocks picks by Ajit Mishra that can offer good returns in short-term
Concor has been trading with a corrective bias for the last two months, after making a new record high at Rs 748 levels in June 2021
 "3 stocks picks by Ajit Mishra that can offer good returns in short-term")
SBI Cards, Syngene International: Two stocks that Gaurav Garg is bullish on
The stock of Syngene International is also sustaining above its important moving averages
 "SBI Cards, Syngene International: Two stocks that Gaurav Garg is bullish on")
Limited near term gains for Syngene International stock in pharma space
Sharp re-rating has turned the stock into the most expensive in the pharma space
 "Limited near term gains for Syngene International stock in pharma space")
Pharma shares gain; Natco, Glenmark, Syngene, Sequent Scientific up over 5%
Patient footfalls are gaining traction in healthcare units as demand from non-Covid-19 patients is gathering pace, according to a November 25 report by CARE Ratings.
 "Pharma shares gain; Natco, Glenmark, Syngene, Sequent Scientific up over 5%")
Syngene Intl joins global consortium of healthcare groups on Covid testing
The consortium, led by Bristol Myers Squibb, will focus on a wide range of aspects from research to clinical diagnostic applications, the company said in a statement
 "Syngene Intl joins global consortium of healthcare groups on Covid testing")
Syngene: Investors with long term view should look at the stock on dips
While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger
 "Syngene: Investors with long term view should look at the stock on dips")
Syngene Int'l hits record high in a weak market, rallies 26% in two weeks
The stock rallied 6.5 per cent to Rs 596.85, surpassing its previous high Rs 594.75, touched on September 15, 2020, on the BSE.
 "Syngene Int'l hits record high in a weak market, rallies 26% in two weeks")
Syngene-HiMedia's Elisa test kit for Covid-19 gets ICMR approval
The product will be launched once it receives approval from the Central Drugs Standard Control Organisation next
 "Syngene-HiMedia's Elisa test kit for Covid-19 gets ICMR approval")
Syngene International rallies 13% in two days; stock nears record high
ICICI Securities expects Syngene's revenues to be back on track as the company is currently operating at 90 per cent capacity.
After a muted Q1, Syngene guides for double-digit top line growth
But ongoing capex and depreciation may weigh on bottom line
 "After a muted Q1, Syngene guides for double-digit top line growth")
JB Chemicals & Pharma, Syngene International hit all-time highs
The stock of Syngene International has soared 24 per cent during the past month, as against a 2 per cent rise in the S&P BSE Sensex.
 "JB Chemicals & Pharma, Syngene International hit all-time highs")
Syngene International gains 5% on healthy March quarter results
The company's profit after tax rose 20 per cent to Rs 120 crore relative to last year's profit of Rs 100 crore.
 "Syngene International gains 5% on healthy March quarter results")
Syngene announces commissioning of first phase of R&D center in Hyderabad
Syngene currently operates through multiple facilities in Bengaluru spread across an area of 1.5 million square feet
